Abstract

BackgroundIdentifying subtypes of complex diseases such as cancer is the very first step toward developing highly customized therapeutics on such diseases, as their origins significantly vary even with similar physiological characteristics. There have been many studies to recognize subtypes of various cancer based on genomic signatures, and most of them rely on approaches based on the signatures or features developed from individual genes. However, the idea of network-driven activities of biological functions has gained a lot of interests, as more evidence is found that biological systems can show highly diverse activity patterns because genes can interact differentially across specific molecular contexts.MethodsIn this study, we proposed an in-silico method to quantify pathway activities with a resolution of genetic interactions for individual samples, and developed a method to compute the discrepancy between samples based on the quantified pathway activities.ResultsBy using the proposed discrepancy measure between sample pathway activities in clustering melanoma gene expression data, we identified two potential subtypes of melanoma with distinguished pathway activities, where the two groups of patients showed significantly different survival patterns. We also investigated selected pathways with distinguished activity patterns between the two groups, and the result suggests hypotheses on the mechanisms driving the two potential subtypes.ConclusionsBy using the proposed approach of modeling pathway activities with a resolution of genetic interactions, potential novel subtypes of disease were proposed with accompanying hypotheses on subtype-specific genetic interaction information.

Highlights

  • Identifying subtypes of complex diseases such as cancer is the very first step toward developing highly customized therapeutics on such diseases, as their origins significantly vary even with similar physiological characteristics

  • Based on the sample annotations regarding the stage of melanoma, we computed what stages of melanoma cases are significantly enriched in each group of patients

  • When melanoma is in Stage II, it indicates that the tumor is in deeper skin than Stage I, with possible ulceration

Read more

Summary

Introduction

Identifying subtypes of complex diseases such as cancer is the very first step toward developing highly customized therapeutics on such diseases, as their origins significantly vary even with similar physiological characteristics. Cancer is one of such complex diseases, where even tumors from the same tissue locations can have strikingly diverse molecular mechanisms for their origins Such high heterogeneity in cancer is one of the main obstacles in treatment, as different driving. The main drawback of such approaches is that they focus on individual genes, while a set of interacting genes constitutes a functional module in many real biological systems. For this reason, using individual genes as features often suffer with the issue of low reproducibility, which indicates the expression levels of genes reflect only some part of discrepancy residing between different subtypes

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.